138 related articles for article (PubMed ID: 28210148)
21. Therapeutic Targeting of AXL Receptor Tyrosine Kinase Inhibits Tumor Growth and Intraperitoneal Metastasis in Ovarian Cancer Models.
Kanlikilicer P; Ozpolat B; Aslan B; Bayraktar R; Gurbuz N; Rodriguez-Aguayo C; Bayraktar E; Denizli M; Gonzalez-Villasana V; Ivan C; Lokesh GLR; Amero P; Catuogno S; Haemmerle M; Wu SY; Mitra R; Gorenstein DG; Volk DE; de Franciscis V; Sood AK; Lopez-Berestein G
Mol Ther Nucleic Acids; 2017 Dec; 9():251-262. PubMed ID: 29246304
[TBL] [Abstract][Full Text] [Related]
22. Tissue Microarray Analyses Suggest Axl as a Predictive Biomarker in HPV-Negative Head and Neck Cancer.
Busch CJ; Hagel C; Becker B; Oetting A; Möckelmann N; Droste C; Möller-Koop C; Witt M; Blaurock M; Loges S; Rothkamm K; Betz C; Münscher A; Clauditz TS; Rieckmann T
Cancers (Basel); 2022 Apr; 14(7):. PubMed ID: 35406601
[TBL] [Abstract][Full Text] [Related]
23. Differential Expression Pattern of Epithelial Mesenchymal Transition Gens: AXL, GAS6, Claudin-1, and Cofilin-1, in Different Stages of Epithelial Ovarian Cancer.
Hassani E; Shekari Khaniani M; Saffari M; Emami Razavi A; Shirkoohi R; Mansoori Derakhshan S
Iran J Public Health; 2019 Sep; 48(9):1723-1731. PubMed ID: 31700829
[TBL] [Abstract][Full Text] [Related]
24. AXL Receptor Tyrosine Kinase as a Promising Therapeutic Target Directing Multiple Aspects of Cancer Progression and Metastasis.
Goyette MA; Côté JF
Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158733
[TBL] [Abstract][Full Text] [Related]
25. Altered expression of AXL receptor tyrosine kinase in gastrointestinal cancers: a promising therapeutic target.
Pidkovka N; Belkhiri A
Front Oncol; 2023; 13():1079041. PubMed ID: 37469409
[TBL] [Abstract][Full Text] [Related]
26. Serum Gas6 and Axl as non-invasive biomarkers of advanced histological stage in primary biliary cholangitis.
Hayashi M; Abe K; Fujita M; Takahashi A; Hashimoto Y; Ohira H
Hepatol Res; 2020 Dec; 50(12):1337-1346. PubMed ID: 32885557
[TBL] [Abstract][Full Text] [Related]
27. Structure-based drug discovery of novel fused-pyrazolone carboxamide derivatives as potent and selective AXL inhibitors.
Fang F; Dai Y; Wang H; Ji Y; Liang X; Peng X; Li J; Zhao Y; Li C; Wang D; Li Y; Zhang D; Zhang D; Geng M; Liu H; Ai J; Zhou Y
Acta Pharm Sin B; 2023 Dec; 13(12):4918-4933. PubMed ID: 38045061
[TBL] [Abstract][Full Text] [Related]
28. Targeting AXL Using the AVB-500 Soluble Receptor and through Genetic Knockdown Inhibits Bile Duct Cancer Growth and Metastasis.
Kim J; Nam G; Shin YK; Vilaplana-Lopera N; Jeung HC; Moon EJ; Lee IJ
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980768
[TBL] [Abstract][Full Text] [Related]
29. Microenvironment-Induced Non-sporadic Expression of the AXL and cKIT Receptors Are Related to Epithelial Plasticity and Drug Resistance.
Jokela TA; Engelsen AST; Rybicka A; Pelissier Vatter FA; Garbe JC; Miyano M; Tiron C; Ferariu D; Akslen LA; Stampfer MR; Lorens JB; LaBarge MA
Front Cell Dev Biol; 2018; 6():41. PubMed ID: 29719832
[TBL] [Abstract][Full Text] [Related]
30. Targeting the AXL signaling pathway in ovarian cancer.
Huang RY; Antony J; Tan TZ; Tan DS
Mol Cell Oncol; 2017; 4(2):e1263716. PubMed ID: 28401178
[TBL] [Abstract][Full Text] [Related]
31. Predicting the Specificity- Determining Positions of Receptor Tyrosine Kinase Axl.
Karakulak T; Rifaioglu AS; Rodrigues JPGLM; Karaca E
Front Mol Biosci; 2021; 8():658906. PubMed ID: 34195226
[TBL] [Abstract][Full Text] [Related]
32. Retraction. A promiscuous liaison between IL-15 receptor and Axl receptor tyrosine kinase in cell death control.
Budagian V; Bulanova E; Orinska Z; Thon L; Mamat U; Bellosta P; Basilico C; Adam D; Paus R; Bulfone-Paus S
EMBO J; 2011 Feb; 30(3):627. PubMed ID: 21285977
[No Abstract] [Full Text] [Related]
33. Correction: Axl Kinase as a Key Target for Oncology: Focus on Small Molecule Inhibitors.
Mol Cancer Ther; 2015 Jun; 14(6):1518. PubMed ID: 25998950
[No Abstract] [Full Text] [Related]
34. AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications.
Zhu C; Wei Y; Wei X
Mol Cancer; 2019 Nov; 18(1):153. PubMed ID: 31684958
[TBL] [Abstract][Full Text] [Related]
35. AXL/AKT axis mediated-resistance to BRAF inhibitor depends on PTEN status in melanoma.
Zuo Q; Liu J; Huang L; Qin Y; Hawley T; Seo C; Merlino G; Yu Y
Oncogene; 2018 Jun; 37(24):3275-3289. PubMed ID: 29551771
[TBL] [Abstract][Full Text] [Related]
36. Gas6/Axl Signaling Pathway in the Tumor Immune Microenvironment.
Tanaka M; Siemann DW
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32660000
[TBL] [Abstract][Full Text] [Related]
37. AXL in cancer: a modulator of drug resistance and therapeutic target.
Tang Y; Zang H; Wen Q; Fan S
J Exp Clin Cancer Res; 2023 Jun; 42(1):148. PubMed ID: 37328828
[TBL] [Abstract][Full Text] [Related]
38. Gas6/AXL pathway: immunological landscape and therapeutic potential.
Zhai X; Pu D; Wang R; Zhang J; Lin Y; Wang Y; Zhai N; Peng X; Zhou Q; Li L
Front Oncol; 2023; 13():1121130. PubMed ID: 37265798
[TBL] [Abstract][Full Text] [Related]
39. Immune Evasion Mechanism and AXL.
Son HY; Jeong HK
Front Oncol; 2021; 11():756225. PubMed ID: 34778071
[TBL] [Abstract][Full Text] [Related]
40. AXL Receptor in Cancer Metastasis and Drug Resistance: When Normal Functions Go Askew.
Auyez A; Sayan AE; Kriajevska M; Tulchinsky E
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638349
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
